148 results on '"Gunst, Jesper"'
Search Results
2. Identifying risk factors for blood culture negative infective endocarditis: An international ID-IRI study
3. Long-term prognosis at 1.5 years after infection with wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron variants
4. Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets
5. Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1
6. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
7. Immunomodulation with IL-7 and IL-15 in HIV-1
8. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity
9. Blood Culture Negative Endocarditis; What Do Concurrent Cardiac Disorders Tell Us?
10. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
11. Determination of camostat and its metabolites in human plasma – Preservation of samples and quantification by a validated UHPLC-MS/MS method
12. Predicting Cognitive Rehabilitation Needs in Patients with Central Nervous System Infections Using Montreal Cognitive Assessment
13. The impact of analytical treatment interruptions and trial interventions on time to viral re‐suppression in people living with HIV restarting ART in cure‐related clinical studies: a systematic review and meta‐analysis.
14. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection
15. Host Receptor Targeting to Treat Covid-19
16. Portraying infective endocarditis: results of multinational ID-IRI study
17. Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission
18. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment
19. Editorial : COVID-19: From bedside to follow-up
20. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence:the randomized phase 2a TITAN trial
21. Editorial: COVID-19: From bedside to follow-up
22. COVID-19: From Bedside to Follow-up
23. The Impact of Analytical Treatment Interruptions and Trial Interventions on Time to Viral Re-Suppression in People Living with HIV Restarting ART in Cure-Related Clinical Studies: A Systematic Review and Meta-Analysis
24. Characteristics of a Danish Post-COVID Cohort Referred for Examination due to Persistent Symptoms Six Months after Mild Acute COVID-19
25. New insight into the mechanisms of achieving antiretroviral therapy-free HIV-1 control
26. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
27. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1:a phase 1b/2a, randomized trial
28. Beyond antiretroviral therapy: early interventions to control HIV-1 infection
29. Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir
30. Single-cell TCR and mRNA sequencing of antigen-specific T cells reveal spatial trajectories from single time points with HLA and VDJ bias
31. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection
32. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
33. Redirector of Vaccine-Induced Effector Responses (RoVER) for Specific Killing of Cellular Targets
34. Modest de novo Reactivation of Single HIV-1 Proviruses in Peripheral CD4+ T Cells by Romidepsin
35. A mycotic abdominal aortic aneurysm caused by Listeria monocytogenes in a patient with HIV infection
36. Distinct SARS-CoV-2 sensing pathways in pDCs driving TLR7-antiviral vs. TLR2-immunopathological responses in COVID-19
37. Long-Term Symptoms among Hospitalized COVID-19 Patients 48 Weeks after Discharge—A Prospective Cohort Study
38. The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection
39. Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients
40. Modest de novo Reactivation of Single HIV-1 Proviruses in Peripheral CD4+ T Cells by Romidepsin
41. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity.
42. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
43. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
44. Persistent Symptoms in Patients Recovering From COVID-19 in Denmark
45. Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety
46. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
47. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
48. Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
49. Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety.
50. Central nervous system infections in the absence of cerebrospinal fluid pleocytosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.